Drug Trial Radar · NCT07586826
Romiplostim N01 Plus ATRA for Persistent Isolated Chemotherapy-Induced Thrombocytopenia After Complete Remission of Gynecologic, Breast, or Lung Solid Tumors
Last checked: Nov 20, 2026Latest source record: May 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
220
Planned (sponsor's estimate)
Start
Dec 22, 2025
Primary completion
Oct 31, 2027
Study completion Dec 31, 2027
Sponsor
- Lead sponsor
- Peking University People's HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Peking University Cancer Hospital and Institute; Cancer Institute and Hospital, Chinese Academy of Medical Sciences; Peking University International Hospital; Shanxi Province Cancer Hospital; Henan Provincial People's Hospital; China-Japan Union Hospital, Sun Yat-sen University Cancer Center; Hebei Medical University Fourth Hospital; Tianjin Medical University Cancer Institute and Hospital
- First posted
- May 14, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a prospective, randomized, open-label, active-controlled study to evaluate the efficacy and safety of Romiplostim N01 plus all-trans retinoic acid (ATRA) compared with Romiplostim N01 alone in adults with persistent isolated chemotherapy-induced thrombocytopenia (PICIT) after complete remission of selected gynecologic, breast, or lung solid tumors, including but not limited to non-small cell lung cancer (NSCLC), ovarian cancer, and breast cancer. Eligible participants will be randomized in a 1:1 ratio to receive Romiplostim N01 plus oral ATRA or Romiplostim N01 alone for 12 weeks, with follow-up through Week 24. The primary outcome is the overall platelet response rate at Week 12, defined as platelet count \>50 x 10\^9/L in at least 2 of the last 3 scheduled platelet assessments up to Week 12. Secondary outcomes include sustained response during Weeks 13 to 24, complete and partial response rates, duration of response, time to response, platelet count changes, platelet transfusion requirements, bleeding events, and safety.
Conditions
- Persistent Isolated Chemotherapy-Induced Thrombocytopenia
- Chemotherapy-Induced Thrombocytopenia
- Gynecologic Cancers
- Ovarian Cancer
- Breast Cancer
- Lung Cancer
- Non-Small Cell Lung Cancer
- Cervical Cancer
- Fallopian Tube Cancer
- Primary Peritoneal Cancer
Interventions
Romiplostim N01Drug
Romiplostim N01 will be administered by subcutaneous injection at an initial dose of 4 mcg/kg once weekly for 12 weeks. The dose may be adjusted according to platelet count: increase by 2 mcg/kg if platelet count is \<50 x 10\^9/L, with a maximum dose of 10 mcg/kg; maintain the current dose if platelet count is \>=50 to \<=200 x 10\^9/L; reduce by 1 mcg/kg if platelet count is \>200 to \<=400 x 10\^9/L; and withhold dosing if platelet count is \>400 x 10\^9/L, then restart at a lower dose after platelet count decreases to approximately 200 x 10\^9/L.
All-trans retinoic acidDrug
All-trans retinoic acid (ATRA) will be administered orally at 10 mg twice daily for 12 weeks. Dose interruption, reduction, or discontinuation may be performed for intolerable toxicity or clinically significant adverse events according to the protocol.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Platelet Response Rate at Week 12Time frame: From randomization to Week 12
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Peking University People's Hospital
Beijing, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.